AUS
NZ
UK
CA
USA
IND
Highlights
- EBR Systems has received FDA acceptance of its PMA application for the WiSE device, moving to a substantive review.
- The FDA expedited the review process, completing its confirmation in just 30 days.
- EBR anticipates FDA approval in Q1 2025, with a commercial launch planned for the same year.
EBR Systems (ASX:EBR) has recently achieved a significant milestone by announcing that the U.S. Food and Drug Administration (FDA) has formally accepted its Premarket Approval (PMA) application for the WiSE device. This acceptance allows the application to proceed to a substantive review, a crucial step in the approval process.
In August, EBR Systems submitted the final module of the PMA application, which initiated a 45-day FDA-mandated filing period to confirm the administrative completeness and adequacy of the technical elements for substantive review. Remarkably, the FDA completed its review in only 30 days, indicating a potentially expedited assessment of the WiSE technology.
Innovative WiSE Technology
The WiSE device, which is approximately the size of a cooked grain of rice, employs proprietary wireless techniques to deliver pacing stimulation directly to the heart’s left ventricle. This innovation aims to address limitations associated with current standard treatments. The device features over 100 carefully assembled miniature electrical components, meticulously arranged by hand before being compacted into its compact cylindrical shape.
Key Assessments During the Review Process
The substantive review will involve a comprehensive evaluation of the PMA application, including critical assessments such as:
- Bioresearch Monitoring (BIMO) Audit: This process ensures the quality and integrity of EBR's clinical trial data while confirming that test subjects were adequately protected.
- Pre-Approval Inspection (PAI): This inspection verifies that EBR's manufacturing and processing practices adhere to Quality System regulations, ensuring that the facility can consistently produce devices that meet approved specifications.
Throughout the substantive review, the FDA will provide feedback and request additional information from EBR before determining the approvability of the WiSE device.
Supporting Clinical Data
EBR’s PMA application is backed by extensive technical documentation and clinical data from all trials conducted to date, including results from the pivotal SOLVE-CRT trial, which successfully achieved its primary efficacy and safety endpoints. Notably, results from the SOLVE-CRT trial were showcased at the Heart Rhythm Society’s conference in May 2023 and were recently published in the esteemed journal JAMA Cardiology, reinforcing the positive outcomes of the device.
Pathway to Commercialization
Designated as a Breakthrough Device, WiSE is set to receive prioritized review and enhanced communication with the FDA. EBR Systems anticipates receiving FDA approval in the first quarter of calendar year 2025 and is on track for commercial launch within the same year. To support these efforts, EBR recently announced a fully underwritten institutional placement and entitlement offer aiming to raise $50 million. This funding is intended to provide sufficient cash flow through the FDA approval process and aid in the early stages of commercialization and revenue growth.
The acceptance of EBR Systems’ PMA application by the FDA marks a critical step toward the potential commercialization of its WiSE technology. With expedited review timelines and robust clinical data backing its efficacy, EBR is poised to bring innovative solutions to heart failure patients in need. As the company approaches anticipated FDA approval and subsequent market introduction, the journey of WiSE continues to evolve, promising advancements in cardiac care.
